![]() |
|
| Type | Public (NYSE: BSX) |
|---|---|
| Founded | 1979 |
| Headquarters | Natick, Massachusetts |
| Key people | John Abele, Founder & Director Peter Nicholas, Founder & Chairman Ray Elliott, CEO Paul LaViolette, COO |
| Industry | Medical Instruments & Supplies |
| Revenue | ▲$8.05 Billion USD (2008) |
| Net income | (▼$2.03 Billion) USD (2008) |
| Employees | 28,600 (2007) |
| Website | www.bostonscientific.com |
The Boston Scientific Corporation (NYSE: BSX) (abbreviated BSC), is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a range of interventional medical specialties, including interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Boston Scientific is well known for the development of the Taxus Stent, a drug-eluting stent which is used to open clogged arteries. This product was at the center of a claim of patent infringement on the part of Boston Scientific, which was found liable for $431 million in damages.[1]
Boston Scientific's main competitors are Johnson
& Johnson, Medtronic, and St. Jude Medical. The company recently
acquired longtime competitor Guidant for approximately $27 billion. The
former Guidant was split between BSC and Abbott
Laboratories. [2] [3]
Navilyst Medical was formed in February 2008 from Boston Scientific's Fluid Management and Vascular Access business units. [4]
|
|